Skip to main content
. 2016 Sep 17;7(43):69976–69990. doi: 10.18632/oncotarget.12099

Figure 2. FGFR4 correlates with RAD51 protein levels and poor clinical outcome in human rectal cancer.

Figure 2

FGFR4 (A) and RAD51 (B) staining intensity in pre-treatment biopsies was scored for responders and non-responders, according to the immunoreactive scoring (IRS) described in the “materials and methods.” The figures show the individual values together with the mean intensity score ± SEM, *p < 0.05 − t-test. Representative staining of FGFR4 (C) and RAD51 (D) in a resected rectal tumor of a patient who did not respond to the neoadjuvant chemoradiotherapy regimen. Scale bar = 100 μm.